Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

PHASE3CompletedINTERVENTIONAL
Enrollment

559

Participants

Timeline

Start Date

February 11, 2015

Primary Completion Date

March 22, 2016

Study Completion Date

December 17, 2018

Conditions
PsoriasisPlaque Psoriasis
Interventions
BIOLOGICAL

Certolizumab Pegol

"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/ mL~* Route of Administration: Subcutaneous use"

BIOLOGICAL

Etanercept

"* Active Substance: Etanercept~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 50 mg / mL~* Route of Administration: Subcutaneous use"

OTHER

Placebo

"* Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use"

Trial Locations (70)

14203

Ps0003 404, Buffalo

20037

Ps0003 316, Washington D.C.

33409

Ps0003 304, West Palm Beach

36608

Ps0003 317, Mobile

46256

Ps0003 310, Indianapolis

60118

Ps0003 313, West Dundee

62703

Ps0003 302, Springfield

72204

Ps0003 306, Little Rock

75246

Ps0003 401, Dallas

77065

Ps0003 403, Houston

77598

Ps0003 311, Webster

78213

Ps0003 406, San Antonio

89052

Ps0003 400, Henderson

90045

Ps0003 307, Los Angeles

90212

Ps0003 301, Beverly Hills

92123

Ps0003 405, San Diego

97223

Ps0003 407, Portland

07044-29

Ps0003 319, Verona

02919

Ps0003 309, Johnston

Unknown

Ps0003 345, Dupnitsa

Ps0003 343, Sofia

Ps0003 344, Plovdiv

Ps0003 342, Varna

Ps0003 353, Pardubice

Ps0003 351, Pardubice

Ps0003 352, Prague

Ps0003 350, Ústí nad Labem

Ps0003 320, Nice

Ps0003 325, Toulouse

Ps0003 374, Friedrichshafen

Ps0003 373, Munich

Ps0003 368, Frankfurt am Main

Ps0003 378, Bochum

Ps0003 371, Wuppertal

Ps0003 370, Mainz

Ps0003 365, Kiel

Ps0003 363, Erfurt

Ps0003 367, Berlin

Ps0003 372, Berlin

Ps0003 375, Berlin

Ps0003 369, Dresden

Ps0003 361, Giessen

Ps0003 362, Hamburg

Ps0003 366, Hanover

Ps0003 381, Orosháza

Ps0003 380, Debrecen

Ps0003 382, Budapest

Ps0003 383, Budapest

Ps0003 384, Budapest

Ps0003 340, Breda

Ps0003 424, Poznan

Ps0003 330, Torun

Ps0003 422, Wroclaw

Ps0003 335, Lublin

Ps0003 338, Warsaw

Ps0003 421, Warsaw

Ps0003 333, Bialystok

Ps0003 334, Katowice

Ps0003 425, Bialystok

Ps0003 427, Gdansk

Ps0003 423, Gdynia

Ps0003 332, Szczecin

Ps0003 336, Warsaw

Ps0003 339, Wroclaw

Ps0003 390, Dundee

Ps0003 391, Hexham

Ps0003 395, Cardiff

Ps0003 393, Edgbaston

Ps0003 394, Liverpool

Ps0003 392, Manchester

All Listed Sponsors
lead

UCB Biopharma S.P.R.L.

INDUSTRY

NCT02346240 - Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) | Biotech Hunter | Biotech Hunter